Establishment Labs (NASDAQ:ESTA) Rating Increased to Buy at Wall Street Zen

Wall Street Zen upgraded shares of Establishment Labs (NASDAQ:ESTA) from a hold rating to a buy rating in a report issued on Saturday morning.

A number of other research firms have also weighed in on ESTA. BTIG Research raised their price objective on shares of Establishment Labs from $86.00 to $88.00 and gave the company a “buy” rating in a research note on Tuesday, February 24th. Citigroup boosted their target price on shares of Establishment Labs from $62.00 to $75.00 and gave the stock a “neutral” rating in a research report on Thursday, December 11th. JPMorgan Chase & Co. upped their target price on shares of Establishment Labs from $71.00 to $80.00 and gave the stock an “overweight” rating in a report on Wednesday, December 17th. Mizuho raised their price target on shares of Establishment Labs from $90.00 to $100.00 and gave the company an “outperform” rating in a research report on Wednesday, February 25th. Finally, Stephens lifted their price target on Establishment Labs from $85.00 to $90.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $87.00.

Establishment Labs Trading Down 1.4%

NASDAQ ESTA opened at $70.38 on Friday. The company has a quick ratio of 2.10, a current ratio of 3.04 and a debt-to-equity ratio of 10.51. Establishment Labs has a 52 week low of $26.56 and a 52 week high of $83.31. The business has a 50 day moving average price of $70.89 and a 200-day moving average price of $59.68. The company has a market cap of $2.06 billion, a price-to-earnings ratio of -40.45 and a beta of 0.91.

Establishment Labs (NASDAQ:ESTA) last issued its earnings results on Tuesday, February 24th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.13. Establishment Labs had a negative return on equity of 201.79% and a negative net margin of 24.19%.The company had revenue of $64.62 million for the quarter, compared to analysts’ expectations of $63.80 million. During the same period last year, the business earned ($1.19) EPS. Establishment Labs’s quarterly revenue was up 45.2% compared to the same quarter last year. As a group, equities analysts expect that Establishment Labs will post -2.41 earnings per share for the current fiscal year.

Institutional Trading of Establishment Labs

Several institutional investors have recently made changes to their positions in the company. Kestra Advisory Services LLC bought a new position in shares of Establishment Labs during the fourth quarter valued at about $47,000. Quarry LP bought a new stake in Establishment Labs in the 3rd quarter worth about $34,000. State of Wyoming bought a new stake in Establishment Labs in the 3rd quarter worth about $71,000. MV Capital Management Inc. purchased a new stake in Establishment Labs in the 4th quarter valued at about $146,000. Finally, Osaic Holdings Inc. increased its stake in Establishment Labs by 900.0% in the 2nd quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock valued at $85,000 after buying an additional 1,800 shares during the last quarter. Institutional investors own 72.91% of the company’s stock.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.